The Patented Medicine Prices Review Board (PMPRB) published the 10th edition of its annual Meds Entry Watch report today. Canada continues to approve more new medicines than the median for Organisation for Economic Co-operation and Development (OECD) countries. Most new medicines come to market with high treatment costs and specialty medicines such as biologic, orphan, and cancer treatments continue to make up a growing share of the new drug landscape.
The Meds Entry Watch, 10th edition report focuses on medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada between 2021 and 2025, and analyzes their uptake, pricing, sales, and availability as of the last quarter of 2024 (Q4-2024).
This publication informs decision makers, researchers, and patients of the evolving market dynamics of emerging therapies in Canadian and international pharmaceutical markets.
